Vnitr Lek 2016, 62(9):688-689

Klinická účinnost a bezpečnost bazálního inzulinového analoga glarginu v léčbě pacientů s diabetes mellitus 2. typu - editorial

Alena Adamíková
Diabetologické centrum Krajské nemocnice T. Bati, a.s., Zlín

Received: August 30, 2016; Published: September 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Adamíková A. Klinická účinnost a bezpečnost bazálního inzulinového analoga glarginu v léčbě pacientů s diabetes mellitus 2. typu - editorial. Vnitr Lek. 2016;62(9):688-689.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the America Diabetes Association and the European Association for Study of Diabetes. Diabetes Care 2015; 38(1): 140-149. Dostupné z DOI: <http://dx.doi.org/10.2337/dc14-2441>. Go to original source... Go to PubMed...
    2. Škrha J, Pelikánová T, Kvapil M. Česká diabetologická společnost. Doporučený postup péče o diabetes mellitus 2. typu. Dostupné z WWW: <www.diab.cz>.
    3. Davies M, Storms F, Shutler S et al. [ATLANTUS Study Group]. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes. Diabetes Care 2005; 28(6): 1282-1288. Go to original source... Go to PubMed...
    4. SPC Toujeo. Dostupné z DOI: <http://dx.doi.org/http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000309/WC500047935.pdf>.
    5. Riddle MC, Bolli GB, Yki-Järvinen H et al. One-year sustained glycemic control and less hypoglycaemia with new insulin glargine 300 U/mL compared with 100 U/mL in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension. Diabetes Obes Metab 2015; 17(9): 835-842. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12472>. Go to original source... Go to PubMed...
    6. Yki-Järvinen K, Bergenstal RM, Bolli GB et al. Less nocturnal hypoglycaemia and weight gain with new insulin glargine 300 U/mL vs 100 U/mL: 1-year results in people with type 2 diabetes using basal insulin + OADs (EDITION 2). Can J Diabetes 2014; 38(5 Suppl): S5. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcjd.2014.07.013>. Go to original source... Go to PubMed...
    7. Bolli GB, Riddle MC, Bergenstal RM et al. New insulin glargine 300 U/mL compared with glargine 100 U/mL in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab 2015; 17(4): 386-394. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12438>. Go to original source... Go to PubMed...
    8. Gerstein HC, Yale JF, Harris SB, et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implemeting New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006; 23(7): 736-742. Go to original source... Go to PubMed...
    9. Yale JF, Harris SB, Berard L et al. A pragmatic self-titration 1 U/say (INSIGHT) algorithm for insulin glargine 300 U/ml (Gla-300) is safe and effective. American Diabetes Association, June 10-14, 2016; 93-LB.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.